Vitamin D may slow progression of low-grade prostate tumors
the ONA take:
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery, new research presented at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver, Colorado has shown.
For the randomized, controlled clinical trial, researchers assigned 37 men with low-grade prostate cancer undergoing elective prostatectomies to receive either 4,000U of vitamin D daily or placebo during the 60-day waiting period prior to surgery. The patients' prostate glands were then removed and examined.
Results showed that men who received vitamin D showed improvements in their prostate tumors while those in the placebo group experienced no changes or their tumors got worse.
The findings suggest that vitamin D supplementation, well below pharmacological levels, may improve less aggressive prostate cancer by decreasing inflammation. It is not clear yet whether vitamin D prevents or treats prostate cancer, but it can prevent lower-grade tumors from becoming aggressive.
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|